异喹啉-萘醌杂种作为PARP-1抑制剂通过DNA损伤和ROS生成诱导胶质瘤细胞凋亡

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL
Vijay Babu Pathi, , , Sunny Kumar, , , Asikul Sk, , , Subhankar Shee, , , Mrinal K. Ghosh*, , and , Biswadip Banerji*, 
{"title":"异喹啉-萘醌杂种作为PARP-1抑制剂通过DNA损伤和ROS生成诱导胶质瘤细胞凋亡","authors":"Vijay Babu Pathi,&nbsp;, ,&nbsp;Sunny Kumar,&nbsp;, ,&nbsp;Asikul Sk,&nbsp;, ,&nbsp;Subhankar Shee,&nbsp;, ,&nbsp;Mrinal K. Ghosh*,&nbsp;, and ,&nbsp;Biswadip Banerji*,&nbsp;","doi":"10.1021/acs.jmedchem.5c01229","DOIUrl":null,"url":null,"abstract":"<p >We report a series of fused isoquinolinone–naphthoquinone hybrid molecules as PARP-1 inhibitors. Our efforts led to the identification of compounds <b>5c</b> and <b>5d</b>, which display potent PARP-1 inhibition in enzymatic assays with IC<sub>50</sub> values of 2.4 and 4.8 nM and demonstrated consistent antiproliferative activity in C6 glioma cells, with IC<sub>5</sub><sub>0</sub> values of 1.34 ± 0.02 and 1.35 ± 0.009 μM, respectively. Notably, both molecules showed similar efficacy in U87MG glioma cells with IC<sub>5</sub><sub>0</sub> values of 1.28 ± 0.03 and 1.33 ± 0.01 μM, respectively. <b>5c</b> and <b>5d</b> induced apoptosis in both glioma cells by promoting PARP cleavage, triggering DNA damage, and increasing ROS. Furthermore, they effectively inhibited cell migration and significantly reduced colony formation in both glioma cells. Thus, the results identify the hybrid isoquinolinone–naphthoquinone scaffolds (<b>5c</b> and <b>5d</b>) as a promising lead hit for PARP-1 inhibition in glioma, offering a new scaffold for future drug development.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 18","pages":"19153–19168"},"PeriodicalIF":6.8000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Isoquinolinone–Naphthoquinone Hybrids as Potent PARP-1 Inhibitors Induce Apoptosis in Glioma via DNA Damage and ROS Generation\",\"authors\":\"Vijay Babu Pathi,&nbsp;, ,&nbsp;Sunny Kumar,&nbsp;, ,&nbsp;Asikul Sk,&nbsp;, ,&nbsp;Subhankar Shee,&nbsp;, ,&nbsp;Mrinal K. Ghosh*,&nbsp;, and ,&nbsp;Biswadip Banerji*,&nbsp;\",\"doi\":\"10.1021/acs.jmedchem.5c01229\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >We report a series of fused isoquinolinone–naphthoquinone hybrid molecules as PARP-1 inhibitors. Our efforts led to the identification of compounds <b>5c</b> and <b>5d</b>, which display potent PARP-1 inhibition in enzymatic assays with IC<sub>50</sub> values of 2.4 and 4.8 nM and demonstrated consistent antiproliferative activity in C6 glioma cells, with IC<sub>5</sub><sub>0</sub> values of 1.34 ± 0.02 and 1.35 ± 0.009 μM, respectively. Notably, both molecules showed similar efficacy in U87MG glioma cells with IC<sub>5</sub><sub>0</sub> values of 1.28 ± 0.03 and 1.33 ± 0.01 μM, respectively. <b>5c</b> and <b>5d</b> induced apoptosis in both glioma cells by promoting PARP cleavage, triggering DNA damage, and increasing ROS. Furthermore, they effectively inhibited cell migration and significantly reduced colony formation in both glioma cells. Thus, the results identify the hybrid isoquinolinone–naphthoquinone scaffolds (<b>5c</b> and <b>5d</b>) as a promising lead hit for PARP-1 inhibition in glioma, offering a new scaffold for future drug development.</p>\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"68 18\",\"pages\":\"19153–19168\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01229\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01229","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

我们报道了一系列融合异喹啉-萘醌杂化分子作为PARP-1抑制剂。我们的努力鉴定出化合物5c和5d,在酶促实验中显示出有效的PARP-1抑制作用,IC50值分别为2.4和4.8 nM,对C6胶质瘤细胞具有一致的抗增殖活性,IC50值分别为1.34±0.02和1.35±0.009 μM。值得注意的是,两种分子对U87MG胶质瘤细胞的作用相似,IC50值分别为1.28±0.03 μM和1.33±0.01 μM。5c和5d通过促进PARP切割、触发DNA损伤和增加ROS诱导两种胶质瘤细胞凋亡。此外,它们有效地抑制细胞迁移并显著减少两种胶质瘤细胞的集落形成。因此,研究结果确定了异喹啉-萘醌杂化支架(5c和5d)是抑制胶质瘤中PARP-1的有希望的先导靶点,为未来的药物开发提供了新的支架。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Isoquinolinone–Naphthoquinone Hybrids as Potent PARP-1 Inhibitors Induce Apoptosis in Glioma via DNA Damage and ROS Generation

We report a series of fused isoquinolinone–naphthoquinone hybrid molecules as PARP-1 inhibitors. Our efforts led to the identification of compounds 5c and 5d, which display potent PARP-1 inhibition in enzymatic assays with IC50 values of 2.4 and 4.8 nM and demonstrated consistent antiproliferative activity in C6 glioma cells, with IC50 values of 1.34 ± 0.02 and 1.35 ± 0.009 μM, respectively. Notably, both molecules showed similar efficacy in U87MG glioma cells with IC50 values of 1.28 ± 0.03 and 1.33 ± 0.01 μM, respectively. 5c and 5d induced apoptosis in both glioma cells by promoting PARP cleavage, triggering DNA damage, and increasing ROS. Furthermore, they effectively inhibited cell migration and significantly reduced colony formation in both glioma cells. Thus, the results identify the hybrid isoquinolinone–naphthoquinone scaffolds (5c and 5d) as a promising lead hit for PARP-1 inhibition in glioma, offering a new scaffold for future drug development.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信